文献速递临床试验与 GCP基础与转化研究

重复经颅磁刺激治疗儿童青少年孤独症谱系障碍:双盲假对照随机临床试验研究方案

Repetitive transcranial magnetic stimulation in children and adolescents with autism spectrum disorder: study protocol for a double-blind, sham-controlled, randomized clinical trial.
PubMed 文献 · Trials · 2025-07-07

本研究为双盲假对照随机临床试验方案,拟纳入40例7-18岁不同临床严重程度的孤独症谱系障碍患者,随机分为活性治疗组(n=20)与假对照组(n=20)。活性组接受18次低频(2 Hz)重复经颅磁刺激,靶点为双侧背外侧前额叶皮质,刺激强度为运动阈值的90%,每次180个脉冲,疗程9周;在基线、治疗后及1个月随访时进行临床、认知和神经生理评估并采集血尿生物标志物。研究旨在评估重复经颅磁刺激相对于假刺激的疗效与安全性。

要点

  • 拟纳入40例7-18岁孤独症谱系障碍患者,活性组与假对照组各20例。
  • 活性组接受18次2 Hz重复经颅磁刺激,强度为运动阈值90%,每次180个脉冲。
  • 治疗靶点为左背外侧前额叶皮质6次、右背外侧前额叶皮质6次、双半球6次。

核心结论

  • 本研究旨在确定一种安全的重复经颅磁刺激方案,作为孤独症谱系障碍现有治疗的补充。
  • 通过评估对重复经颅磁刺激最敏感的认知域及临床和生化特征,本研究可能有助于优化孤独症谱系障碍治疗并改善儿科人群的治疗结局。

研究设计与样本

  • 双盲、假对照、随机临床试验方案。
  • 拟纳入40例7-18岁不同临床严重程度的孤独症谱系障碍患者,随机分为活性治疗组(n=20)与假对照组(n=20)。

主要发现

  • 活性组每次接受低频(2 Hz)重复经颅磁刺激,强度为运动阈值的90%,每次180个脉冲。
  • 活性组共接受18次治疗,疗程9周;靶点为左背外侧前额叶皮质(6次)、右背外侧前额叶皮质(6次)及双半球(6次)。
  • 在基线、治疗后及1个月随访时进行临床、认知和神经生理评估。
  • 在每个时间点采集血、尿样本,评估色氨酸代谢物、神经营养因子、神经递质和炎症介质等生物标志物的变化。
  • 通过半结构化访谈和不良事件报告监测安全性。

关键数值与推荐

  • 低频重复经颅磁刺激参数为2 Hz、运动阈值的90%、每次180个脉冲。
  • 治疗分配为左背外侧前额叶皮质6次、右背外侧前额叶皮质6次、双半球6次,共18次,疗程9周。
  • 评估时间点为基线、治疗后及1个月随访。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prevalence of autism spectrum disorder (ASD) has significantly increased over recent decades, representing a serious public health issue. Neurobiological characteristics of ASD include imbalances in cortical excitation and inhibition, along with disruptions in neural network connectivity. Repetitive transcranial magnetic stimulation (rTMS) may provide a therapeutic option when cognitive-behavioral therapy alone is insufficient to alleviate core symptoms. This article outlines the protocol for a double-blind, sham-controlled, randomized study assessing low-frequency rTMS targeting the bilateral dorsolateral prefrontal cortex (DLPFC) in children and adolescents with ASD. The objective is to evaluate the efficacy of rTMS compared to sham stimulation. METHODS: Forty patients with ASD, aged 7-18 years and with different levels of clinical severity, will be randomized into an active treatment group (n = 20) and a sham control group (n = 20). Each participant will receive 18 low-frequency (2 Hz) rTMS sessions over 9 weeks, administered at 90% of the motor threshold with 180 pulses per session. Treatment will target the left DLPFC (six sessions), the right DLPFC (six sessions), and both hemispheres (six sessions). Clinical, cognitive, and neurophysiological assessments will be conducted at baseline, post-treatment, and 1-month follow-up. Biological samples (blood, urine) will be collected at each time point to evaluate changes in various biomarkers, including tryptophan metabolites, neurotrophic factors, neurotransmitters, and inflammatory mediators. Safety will be monitored through semi-structured interviews and adverse event reporting. DISCUSSION: This study aims to identify a safe rTMS protocol for ASD that could complement existing therapies. By assessing the cognitive domains and the clinical and biochemical profiles most responsive to rTMS, this study may contribute to optimize ASD treatments and enhance therapeutic outcomes in pediatric populations. TRIAL REGISTRATION: The study protocol is registered at "ClinicalTrials.gov" with the following ID: NCT06069323.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Savino R, Davinelli S, Polito AN, et al. Repetitive transcranial magnetic stimulation in children and adolescents with autism spectrum disorder: study protocol for a double-blind, sham-controlled, randomized clinical trial. Trials. 2025. PMID: 40619411. doi:10.1186/s13063-025-08946-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。